Page 49 - Nasdaq First News Today : Breaking News, Live Updates & Top Stories | Vimarsana

VEF updated share buyback mandate The Board of Directors of VEF announces its decision to approve a new and broader share buyback mandate. This mandate replaces previously communicated mandates from June 20, 2019 and May 22, 2018. The new mandate allows VEF to buy up to 22m SDRs for a maximum of USD 10m in total. The purpose of the additional mandate is to allow management the flexibility to create additional shareholder value and optimize the Company's capital structure as and when deemed appropriate as well as buy back shares to be delivered to the participants under the Company's long-term...

Media and Games Invest: CFO and board member buys MGI shares DGAP-News: Media and Games Invest plc / Key word(s): Miscellaneous 25.01.2021 / 14:57 Media and Games Invest: CFO and board member buys MGI shares On January 18, 2021, CFO Paul Echt and Deputy Chairman Tobias M. Weitzel acquired shares in Media and Games Invest. CFO Paul Echt has purchased on various trading venues 40,320 shares for 111,388.74 EUR, corresponding to an average price of 2.76 EUR. The details are shown in the table below. Deputy Chairman Tobias M. Weitzel has purchased 25,270 shares in Germany for 70,310.71 EUR, cor...

About Faron Pharmaceuticals Ltd Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine de...

Entain announces a recommended cash offer to the shareholders of Enlabs AB USA - English Dela den här artikeln   This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer...

About Faron Pharmaceuticals Oy Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen® (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. ...